How do you counsel patients eligible for the RSV vaccines? What do the results of the RENOIR and AReSVi trials tell us and how do they compare? How should we interpret vaccine trials in the first place? Tune in to the fourth episode of Beyond Journal Club, a new series brought to you by Core IM in collaboration with NEJM Group.Sponsor: Pathway FREE evidence-based clinical decision support app. Guideline summaries, interactive algorithms, landmark trials & moreShow Notes & TranscriptTime Stamps:(02:30) | Epidemiology of RSV(03:46) | Development of RSV vaccine(05:55) | Vaccine trial design(12:22) | ARESVI and RENOIR Trials(18:18) | Who should we recommend the RSV vaccine to?(19:50) | What don’t we know?Tags: IMCore, CoreIM, primary care, infectious disease, nurse practitioner, pharmacist, physician assistantFind the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840Our Sponsors:* Check out Branch Basics: https://branchbasics.com/COREIM and use the code CoreIM for 15% * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Washington Red Raspberries: https://redrazz.orgAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related